 Combining eCOA and Ground-Breaking Movement Disorders Digital Biomarker Platform to Evaluate and Predict PD Severity. Horsham, PA, Dec. 14, 2022 GLOBE NEWSWIRE Horsham, Pa.; December 14, 2022 Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization focused on Parkinsons Disease research to deploy remote technology that captures study participants ... The post Clinical ink Selected for Global Late Phase Parkinsons Disease Progra... 